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Abstract
Striatal adenosine A2A receptors (A2ARs) are highly expressed in medium spiny neurons (MSNs) of the indirect efferent
pathway, where they heteromerize with dopamine D2 receptors (D2Rs). A2ARs are also localized presynaptically in cortico-
striatal glutamatergic terminals contacting MSNs of the direct efferent pathway, where they heteromerize with adenosine
A1 receptors (A1Rs). It has been hypothesized that postsynaptic A2AR antagonists should be useful in Parkinson’s disease,
while presynaptic A2AR antagonists could be beneficial in dyskinetic disorders, such as Huntington’s disease, obsessive-
compulsive disorders and drug addiction. The aim or this work was to determine whether selective A2AR antagonists may be
subdivided according to a preferential pre- versus postsynaptic mechanism of action. The potency at blocking the motor
output and striatal glutamate release induced by cortical electrical stimulation and the potency at inducing locomotor
activation were used as in vivo measures of pre- and postsynaptic activities, respectively. SCH-442416 and KW-6002 showed
a significant preferential pre- and postsynaptic profile, respectively, while the other tested compounds (MSX-2, SCH-420814,
ZM-241385 and SCH-58261) showed no clear preference. Radioligand-binding experiments were performed in cells
expressing A2AR-D2R and A1R-A2AR heteromers to determine possible differences in the affinity of these compounds for
different A2AR heteromers. Heteromerization played a key role in the presynaptic profile of SCH-442416, since it bound with
much less affinity to A2AR when co-expressed with D2R than with A1R. KW-6002 showed the best relative affinity for A2AR co-
expressed with D2R than co-expressed with A1R, which can at least partially explain the postsynaptic profile of this
compound. Also, the in vitro pharmacological profile of MSX-2, SCH-420814, ZM-241385 and SCH-58261 was is in
accordance with their mixed pre- and postsynaptic profile. On the basis of their preferential pre- versus postsynaptic actions,
SCH-442416 and KW-6002 may be used as lead compounds to obtain more effective antidyskinetic and antiparkinsonian
compounds, respectively.
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Introduction
The striatum is the major input structure of the basal ganglia
[1]. More than ninety five percent of striatal neurons are c-
aminobutyric-acidergic (GABAergic) medium spiny neurons
(MSNs). These neurons receive two main inputs: glutamatergic
afferents from cortical, thalamic and limbic areas and dopami-
nergic afferents from the substantia nigra pars compacta and the
ventral tegmental area [1]. MSNs are efferent neurons that give
rise to the two efferent pathways of the basal ganglia, the ‘direct’
and ‘indirect’ striatal efferent pathways [1]. It is generally
accepted that stimulation of the direct and indirect pathways
results in motor activation and motor inhibition, respectively, and
that smooth motor drive results from the counterbalanced
influence of the direct and indirect pathways on the neural
activity of the output structures [2,3]. Direct MSNs express
dopamine receptors predominantly of the D1 receptor (D1R)
subtype, whereas indirect MSNs are known for their high
expression of dopamine D2 receptors (D2Rs) and adenosine A2A
receptors (A2ARs) [1,4,5].
There is clear evidence for the existence of postsynaptic
mechanisms in the control of glutamatergic neurotransmission to
the indirect MSN by at least two reciprocal antagonistic
interactions between A2AR and D2R [4]. In one type of
interaction, A2AR and D2R are forming heteromers and, by
means of an allosteric interaction, A2AR counteracts the D2R-
mediated inhibitory modulation of the effects of NMDA receptor
stimulation in the indirect MSN, which includes Ca2+ influx,
transition to the up-state and neuronal firing in the up-state [6,7].
This interaction has been suggested to be mostly responsible for
the locomotor depressant and activating effects of A2AR agonist
and antagonists, respectively [4]. The second type of interaction
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involves A2AR and D2R that do not form heteromers, but most
probably homomers [4]. In this interaction, which takes place at
the level of adenylyl-cyclase (AC), stimulation of Gi-coupled D2R
counteracts the effects of Golf-coupled A2AR [4]. Due to a strong
tonic effect of endogenous dopamine on striatal D2R, this
interaction keeps A2AR from signaling through AC. However,
under conditions of dopamine depletion or with blockade of D2R,
A2AR-mediated AC activation is unleashed. This is biochemically
associated with a significant increase in the phosphorylation of
PKA-dependent substrates, which increases gene expression and
the activity of the indirect MSN, producing locomotor depression
(reviewed in ref. [4]). This interaction seems to be the main
mechanism responsible for the locomotor depression induced by
D2R antagonists. Thus the motor depressant and most biochem-
ical effects induced by genetic or pharmacologic blockade of D2R
are counteracted by the genetic or pharmacological blockade of
A2AR [8–10].
Striatal A2ARs are not only localized postsynaptically but also
presynaptically, in glutamatergic terminals, where they hetero-
merize with A1 receptors (A1Rs) and where their stimulation
facilitates glutamatergic neurotransmission [5,11]. Interestingly,
presynaptic A2ARs are preferentially localized in glutamatergic
terminals of cortico-striatal afferents to the direct MSN [5].
According to the widely accepted functional basal circuitry model
[2,3], blockade of postsynaptic A2AR localized in the indirect
MSN should produce motor activation (by potentiating D2R-
mediated effects by means of A2AR-D2R receptor interactions).
On the other hand, according to the same model, blockade of
presynaptic A2AR localized in the cortico-striatal glutamatergic
terminals that make synaptic contact with the direct MSN should
decrease motor activity (by inhibiting glutamate release). The
preferential locomotor-activating effects of systemically adminis-
tered A2AR receptor antagonists can be explained by a stronger
influence of a tonic adenosine and A2AR receptor-mediated
modulation of the indirect pathway versus the direct pathway
under basal conditions. In any case, the potency at inducing
locomotor activation can be used as an in vivo measure of the
ability of an A2AR antagonist to block postsynaptic striatal A2AR.
Recently we have established an in vivo model that evaluates the
efficacy of cortico-striatal glutamatergic neurotransmission to the
direct MSN, by quantifying the correlation between the current
delivered into the orofacial premotor cortex and the concomitant
electromyographic response elicited in the jaw muscles [5]. In this
model, A2AR or D1R antagonists were able to counteract the
motor output induced by cortical electrical stimulation, which
can only be explained by blockade of striatal presynaptic A2AR or
postsynaptic D1R, respectively [5,12].
Receptor heteromer is defined as a macromolecular complex
composed by at least two (functional) receptor units with
biochemical properties that are demonstrably different from those
of its individual components [13]. Specific ligand binding
characteristics are one of those properties [13,14]. The aim of
the present study was, first, to investigate the possible existence of
different pre- and postsynaptic profiles of several A2AR antago-
nists. The potency at blocking the motor output and striatal
glutamate release induced by cortical electrical stimulation and the
potency at inducing locomotor activation were used as in vivo
measures of pre- and postsynaptic activities, respectively. Second,
we wanted to evaluate if the different pre- and postsynaptic profiles
could be related to different affinities that A2AR could have for
those compounds when forming heteromers with either A1R or
D2R. In fact, the results strongly suggest that heteromerization
plays a key role in the pre- and postsynaptic profile of A2AR
antagonists.
Materials and Methods
Ethics Statement
All animals used in the study were handled in accordance with
the National Institutes of Health Animal care guidelines. The
animal research conducted to perform this study was approved by
the NIDA IRP Animal Care and Use Committee (under the
auspices of protocol 09-BNRB-73) on 12/7/2009.
Animals
Male Sprague-Dawley rats (Charles River Laboratories, Wil-
mington, MA) weighting between 300–350 g were used in these
experiments. Rats were housed 2 per cage and they maintained at
a temperature of 2262uC on a regular 12-h light–dark cycle. Food
and water were available ad libitum.
Adenosine A2AR antagonists
The following A2AR antagonists were used: 2-(2-Furanyl)-7-[3-(4-
methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyr-
imidin-5-amine (SCH-442416), 2-(2-Furanyl)-7-(2-phenylethyl)-7H-
pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine (SCH-58261),
2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperaziny-
l]ethyl]-7H-pyrazolo[4,3-e][1,2,4]-triazolo[1,5-c]pyrimidin-5-amine
(SCH-420814), 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]
triazin-5-ylamino]ethyl)phenol (ZM-241385), (E)-1, 3-diethyl-8-(3,4-
dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-
6002), (E)-3-(3-hydroxypropyl)-8-[2-(3-methoxyphenyl)vinyl]-7-meth-
yl-1-prop-2-ynyl-3,7-dihydropurine-2,6-dione (MSX-2) and its water-
soluble phosphate prodrug (E)-phosphoric acid mono-(3-{8-[2-(3-
methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetra-
hydropurin-3-yl}propyl) ester disodium salt (MSX-3). MSX-3 is a
water-soluble phosphate pro-drug of MSX-2; in vivo MSX-3 is readily
converted to the A2AR antagonist MSX-2 (Sauer et al., 2002). For their
systemic administration, the compounds were prepared as follows:
SCH-442416 and SCH 58261 were suspended in a solution of
5% dimethyl- sulfoxide (DMSO) (Sigma-Aldrich, St. Louis,MI),
5% TWEEN80 (Sigma-Aldrich, St. Louis, MI) and 90% ddH2O;
SCH-420814 was suspended in a solution of 20% PEG400, 40%
b-cyclodextrin and 40% Lutrol 1% (in ddH2O); ZM-241385 was
suspended in a solution of 15% DMSO, 10% TWEEN80 and
75% ddH2O; KW-6002 was suspended in a solution of 8%
TWEEN80 and 92% ddH2O; MSX-3 was dissolved in sterile
saline (with 3 ml/ml saline of 1 M NaOH solution, final pH 7.4).
All drugs but MSX-3 (Sigma-Aldrich, St. Louis, MI) were
provided by CHDI Foundation Inc. (Los Angeles, CA, US).
SCH-420814 was administered subcutaneously (s.c.) at 1 ml/kg
and the other drugs were administered via intraperitonal (i.p.)
injection at volume of 2 ml/kg.
Locomotor Activity
Locomotor activity was measured by placing the animals
individually in motility soundproof chambers (50650 centimeters;
Med Associates Inc., VT). Locomotion was measured by counting
the number of breaks in the infrared beams of the chambers. The
animals were placed in individual acrylic chambers at noon on the
day of testing. A lamp inside each chamber remained lit during
this period. Following 90 min of habituation, the rats were injected
i.p. with different doses of each compound or vehicle and
locomotor activity was recorded for 90 min after the drug or
vehicle administration. All the animals were tested only once. The
effect of different doses of the A2AR antagonists on locomotor
activity were analyzed using a one-way analysis of variance
(ANOVA), followed by Newman-Keuls’ post-hoc test.
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Surgical procedures
Rats were anesthetized with 3 ml/kg of Equithesin (4.44 g of
chloral hydrate, 0.972 g of Na pentobarbital, 2.124 g of MgSO4,
44.4 ml of propylene glycol, 12 ml of ethanol and distilled H2O up
to 100 ml of final solution; NIDA Pharmacy, Baltimore, MD) and
implanted unilaterally with bipolar stainless steel electrodes,
0.15 mm in diameter (Plastics One, Roanoke, VA), into the
orofacial area of the lateral agranular motor cortex (3 mm
anterior, 3 and 4 mm lateral, and 4.2 mm below bregma). The
electrodes and a head holder (connected to a swivel during
stimulation) were fixed on the skull with stainless steel screws and
dental acrylic resin. For the experiments with electromyographic
(EMG) recording, electrodes were also implanted in mastication
muscles (during the same surgical procedure). Two 5 mm-long
incisions were made in the skin on the upper and lower jaw areas
to expose the masseter and the lateral pterygoid muscles. Two
silicon rubber-coated coiled stainless steel recording electrodes
(Plastics One, Roanoke, VA) were slipped below the skin from the
incision in the skull until the tips showed up from the incisions in
the jaw. The bare tips of the electrodes were then held in contact
with the masseter and the lateral pterygoid muscles and the skin
was closed with surgical staples. The other end of the recording
electrodes was encased in a molded plastic pedestal with a round
threaded post which was attached to an electrical swivel and then
to a differential amplifier (Grass LP511, Grass Instruments,
Warwick, RI). The pedestal was secured to the skull with dental
cement together with the stimulation electrodes. For the in vivo
microdialysis experiments, concentric microdialysis probes with 2-
mm long dialysis membranes (Eicom Corp., Tokio, Japan) were
implanted respectively into the striatum ipsilateral to the
stimulation electrodes (0.0 mm AP, 4.5 ML and 7.0 mm DV).
EMG recording and power correlation analysis
Rats were placed in individual bowl chambers. Both stimulation
electrodes and recording electrodes were attached using flexible
shielded cabling to a four channel electrical swivel. Stimulation
electrodes were connected to two-coupled constant current isolation
units (PSIU6X, Grass Instruments West Warwick, RI) driven by an
electrical stimulator (Grass S88X; Grass Instruments). The
recording electrodes were connected to a differential amplifier
(Grass LP511, West Warwick, RI). This configuration allows the rat
to move freely while the stimulation and EMG recordings are taking
place. After 60 min of habituation, biphasic current pulse trains
(pulse of 0.1 ms at 120–200 mA; 100 Hz, 160 ms trains repeating
once per 2 seconds) were delivered. The current intensity was
adjusted to the threshold level, defined as the minimal level of
current intensity allowing at least 95% of the stimulation pulses to
elicit a positive EMG response. Positive EMG response was defined
as at least 100% increase of the peak to peak amplitude respect to
the background tonic EMG activity lasting more than 100 ms or at
least 70% increase in the power of the EMG signal respect to the
baseline. Positive EMG responses always matched observable small
jaw movements. The threshold level was different for each animal
but it was very stable and reproducible once established. The
threshold level was in the 100 to 150 mA range for most cases and it
reached 200 mA in a few (6) animals. Animals that failed to show a
positive EMG response with electrical cortical stimulation intensities
of 200 mA were discarded from the experimental procedure (less
than 10%). Both stimulator monitoring and the amplified and
filtered EMG signal (20,000 times gain, bandwidth from 10 to
1,000 Hz with a notch filter set at 60 Hz) were directed to analog-
to-digital converter for recording (Lab-Trax-4, World Precision
Instruments, Sarasota, FL) and backup (NI 9215, National
Instruments, Austin, TX) and digitized at a sampling rate of
10,000 samples/second. Recordings of the digitized data were made
using the software Data Trax2 software (World Precision
Instruments) and LabVIEW SignalExpress (National Instruments).
A power correlation analysis was used to quantify the correlation
between the stimulation pulses of current delivered into the orofacial
motor cortex (input signal; mA) and the elicited EMG response in
the jaw muscles (output signal; mV). Decrease in the power
correlation coefficient (PCC) between these two signals is meant
to describe a decrease in the efficacy of the transmission in the
neural circuit. Off-line, both signals were rectified and the root
mean square (RMS) over each period of the stimulation pulses was
calculated in the recorded signals using Data Trax2 software. The
transformed data (RMS) from the stimulator monitor and the EMG
were then exported with a time resolution of 100 samples/second to
a spreadsheet file. The stimulation signal values were used as a
reference to select data in a time window of 320 ms starting at the
beginning of each train of pulses. This time window was chosen to
ensure the analysis of any EMG response whose occurrence or
length was delayed from the onset of the stimulation trains and to
maximize the exclusion from the analysis of spontaneous jaw
movements not associated with the stimulation. Pearson’s correla-
tion between the RMS values from the stimulation and EMG
signals was then calculated for each experimental subject. PCC was
calculated using the data recorded 40 min after the administration
of the dose of any compound or vehicle. The effects of the different
doses of A2AR antagonists on PCC were analyzed by a one-way
ANOVA, followed by Dunnett’s post-hoc test.
In vivo microdialysis
The experiments were performed on freely moving rats 24 h
after probe implantation. An artificial cerebrospinal solution of (in
mM) 144 NaCl, 4.8 KCl, 1.7 CaCl2, and 1.2 MgCl2 was pumped
through the microdialysis probe at a constant rate of 1 ml/min.
After a washout period of 90 min, dialysate samples were collected
at 20-min intervals. After 60 min of collecting samples for baseline,
the rats were injected either with the A2AR antagonists KW-6002
or SCH-442416. Both compounds were compared to vehicle
controls (5% DMSO, 5% of TWEEN80 and 90% of ddH2O).
After 20 min from drug or vehicle injection, electrical stimulation
pulses were applied through the electrodes implanted in the
orofacial motor cortex for 20 min (pulse of 0.1 ms at 50–150 mA;
100 Hz, 160 ms trains repeating once6second) and samples were
collected for 2 additional hours. Glutamate content was measured
by reverse-phase HPLC coupled to a flourimetric detector
(Shimadzu Inc., Tokio, Japan) [15]. Glutamate values were
transformed as percentage of the mean of the three values before
the drug or vehicle injection and transformed values were
statistically analyzed. The effect of KW-6002, SCH-442416 and
vehicle were analyzed using a one-way ANOVA for repeated
measures followed by a Tukey’s post-hoc test.
Cell clones
To obtain CHO cells expressing single receptors or co-
expressing A2AR and A1R or A2AR and D2R, the human cDNAs
for A1R or D2R cloned in pcDNA3.1 vector (containing a
geneticin resistance gene) were used. The human A2AR was cloned
into a pcDNA3.1/Hygro vector with a hygromycin resistance
gene. For single transfections, CHO cells were transfected with the
cDNA corresponding to A2AR, A1R or D2R using lipofectamine
(Invitrogen, Carlsbad, USA) method following the instructions of
the supplier. 24 h after transfection the selection antibiotic was
added at a concentration that was previously determined by a
selection antibiotic test. Antibiotic resistant clones were isolated in
the presence of the selection antibiotic (1200 mg/ml geneticin or
Pre- and Postsynaptic A2A Receptor Antagonists
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1000 mg/ml hygromycin). After an appropriate number of days/
passes, several stable lines were selected and cultured in the
presence of the selection antibiotic (600 mg/ml geneticin or
300 mg/ml hygromycin). To obtain clones co-expressing A2AR
and A1R or A2AR and D2R, CHO cells expressing high affinity
A2AR (obtained as above described) were transfected with the
human cDNAs for A1R or D2R cloned in pcDNA3.1 vector using
lipofectamine. After an appropriate number of days/passes stable
lines were selected and cultured in the presence of the selection
antibiotic. The receptor(s) expression in the cell clones was first
detected by dot-blot of cell lysates using commercial available
antibodies and wild-type CHO cells lysates as negative basal
staining. Positively moderated stained clones were grown to obtain
membranes in which the receptor expression was quantified by
radioligand-binding experiments (see Results).
Bioluminescence Resonance Energy Transfer (BRET)
assays
The fusion proteins A2AR-Renilla Luciferase (A2AR-RLuc), A1R-
Yellow Fluorescence Protein (A1R-YFP) and D2R-YFP were
prepared and characterized as described elsewhere [16]. The
cDNA encoding serotonin 5HT2B-YFP receptor was kindly
provided by Dr. Irma Nardi (University of Pisa, Italy). CHO cells
were transiently transfected with the corresponding fusion protein
cDNA (see Figure legends) using lipofectamine. Cells were
incubated (4 h) with the corresponding cDNA together with
lipofectamine and Opti-MEM medium (Invitrogen). After 4 hours,
the medium was changed to a fresh complete culture medium.
Twenty-four hours after transfection, cells were washed twice in
quick succession in HBSS with 10 mM glucose and scraped in
0.5 ml of the same buffer. To control the cell number, sample
protein concentration was determined using a Bradford assay kit
(Bio-Rad, Munich, Germany) using bovine serum albumin
dilutions as standards. To quantify fluorescence proteins, cells
(20 mg protein) were distributed in 96-well microplates (black
plates with a transparent bottom) and fluorescence was read at
400 nm in a Fluo Star Optima Fluorimeter (BMG Labtechnol-
ogies, Offenburg, Germany) equipped with a high-energy xenon
flash lamp, using a 10 nm bandwidth excitation filter. Receptor-
fluorescence expression was determined as fluorescence of the
sample minus the fluorescence of cells expressing protein-Rluc
alone. For BRET measurements, the equivalent of 20 mg of cell
protein were distributed in 96-well microplates (Corning 3600,
white plates; Sigma) and 5 mM coelenterazine H (Molecular
Probes, Eugene, OR) was added. After 1 minute of adding
coelenterazine H, the readings were collected using a Mithras LB
940, which allows the integration of the signals detected in the
485 nm-short- (440–500 nm) and the 530 nm-long-(510–590 nm)
wavelength filters. To quantify receptor-Rluc expression lumines-
cence readings were performed after 10 minutes of adding 5 mM
coelenterazine H. The net BRET is defined as [(long-wavelength
emission)/(short-wavelength emission)]-Cf where Cf corresponds
to [(long-wavelength emission)/(short-wavelength emission)] for
the Rluc construct expressed alone in the same experiment.
Radioligand binding experiments
Cells were disrupted with a Polytron homogenizer (PTA 20 TS
rotor, setting 3; Kinematica, Basel, Switzerland) for two 5 s-periods
in 10 volumes of 50 mM Tris-HCl buffer, pH 7.4 containing a
proteinase inhibitor cocktail (Sigma, St. Louis, MO, USA). Cell
debris was removed by centrifugation at 1,500 g for 5 min at 4uC
and membranes were obtained by centrifugation at 105,000 g
(40 min, 4uC). Membranes were resuspended and centrifuged
under the same conditions. The pellet was stored at220uC, washed
once more as described above and resuspended in 50 mM Tris-HCl
buffer for immediate use. Membrane protein was quantified by the
bicinchoninic acid method (Pierce Chemical Co., Rockford, IL,
USA) using bovine serum albumin dilutions as standard. For
competition experiments, membrane suspensions (0.2 mg of
protein/ml) were incubated for 2 h at 25uC in 50 mM Tris-HCl
buffer, pH 7.4, containing 10 mM MgCl2 and 0.2 U/ml of
adenosine deaminase (ADA, EC 3.5.4.4; Roche, Basel, Switzerland)
with the indicated free concentration of the A1R, A2AR, or D2R
antagonist [3H]DPCPX (GE Healthcare, UK), [3H]ZM-241385, or
[3H]YM-09151-2, respectively (NEN Perkin Elmer, Wellesley, MA,
USA) or the A1Ragonist [
3H](R)-PIA (Moravek Biochemicals Inc.,
Brea, CA, USA) and increasing concentrations of DPCPX, ZM-
241385, YM-09151-2, the A2AR agonist CGS-21680 or the tested
A2AR antagonist (all provided by CHDI Foundation Inc.). Non-
specific binding was determined in the presence of 11 mM of the
corresponding non-radiolabelled ligand. Free and membrane-
bound ligand were separated by rapid filtration of 500 ml aliquots
in a cell harvester (Brandel, Gaithersburg, MD, USA) through
Whatman GF/C filters embedded in 0.3% polyethylenimine that
were subsequently washed for 5 s with 5 ml of ice-cold 50 mM Tris-
HCl buffer. The filters were incubated with 10 ml of Ecoscint H
scintillation cocktail (National Diagnostics, Atlanta, GA, USA)
overnight at room temperature and radioactivity counts were
determined using a Tri-Carb 1600 scintillation counter (PerkinEl-
mer, Boston, MA, USA) with an efficiency of 62% [17]. All
displacers were dissolved in DMSO and diluted in the binding
medium. The DMSO concentration in the binding incubates was
less than 0.5% and, at this concentration, it did not affect agonist or
antagonist affinity for their respective receptors.
Binding data analysis
Radioligand competition curves were analyzed by nonlinear
regression using the commercial Grafit curve-fitting software
(Erithacus Software, Surrey, UK), by fitting the binding data to the
mechanistic two-state dimer receptor model [18,19]. Since there is
now abundant evidence for GPCR oligomerization, including
A1R, A2AR and D2R [20–23] and the minimal functional unit of
GPCRs in biological tissues seems to imply dimerization [23], this
model considers a homodimer as the minimal structural unit of the
receptor. Here, we also consider the possibility of a homodimer as
the minimal structural unit of a receptor forming homomers or
forming heteromers with another receptor. To calculate the
macroscopic equilibrium dissociation constants the following
equation for a competition binding experiment deduced previously
[19,24] was considered:
A
total bound
~ KDA2Az 2A
2 z KDA2AB = KDAB
 
RT =
KDA1KDA2 z KDA2Az A
2 z

KDA2 AB = KDAB z KDA1KDA2B = KDB1
z KDA1KDA2B
2 = KDB1KDB2ð Þ

z Anon{specific bound
ð1Þ
where A represents free radioligand (the adenosine A1R or A2AR or
dopamine D2R antagonist [
3H]DPCPX, [3H]ZM-241385 or
[3H]YM-09151-2, respectively or the A1R agonist [
3H](R)-PIA)
concentration, RT is the total amount of receptor dimers and KDA1
and KDA2 are the macroscopic equilibrium dissociation constants
describing the binding of the first and the second radioligand
molecule (A) to the dimeric receptor; B represents the assayed
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competing compound concentration, and KDB1 and KDB2 are,
respectively, the macroscopic equilibrium dissociation constants for
the binding of the first ligand molecule (B) to a dimer and for the
binding of the second ligand molecule (B) to the semi-occupied
dimer; KDAB is the hybrid equilibrium radioligand/competitor
dissociation constant, which is the dissociation constant of B binding
to a receptor dimer semi-occupied by A.
When the radioligand A shows non-cooperative behaviour, eq.
(1) can be simplified to eq. (2) due to the fact that KDA2 = 4KDA1
[19,25] and, therefore, KDA1 is enough to characterize the binding
of the radioligand A:
A
total bound
~ 4KDA1Az 2A
2 z 4KDA1AB = KDAB
 
RT =
4KDA1
2 z 4KDA1Az A
2

z4KDA1AB = KDAB z 4KDA1
2B = KDB1
z 4KDA1
2B2 = KDB1KDB2ð Þ

z Anon{specific bound
ð2Þ
Binding to GPCRs quite often displays negative cooperativity.
Under these circumstances KD2/KD1.4 and then KD1 and KD2
represent the ‘‘high-affinity’’ and the ‘‘low-affinity’’ binding sites,
respectively. On the other hand, for positive cooperativity, KD2/
KD1,4 and then KD2 represents the ‘‘high-affinity’’ and KD1
represents the ‘‘low-affinity’’binding sites [25]. The two-state dimer
model also introduces a cooperativity index (DCB). The dimer
cooperativity index for the competing ligand B is calculated as
[19,25]:
DCB ~ log 4KDB1= KDB2ð Þ
The way the index is defined is such that its value is ‘‘0’’ for non-
cooperative binding, positive values of DC indicate positive
cooperativity, whereas negative values imply negative cooperativ-
ity [14,19].
In experimental conditions when both the radioligand A and the
competitor B (i.e., most adenosine A2A receptor antagonist tested in
the present study) show non-cooperativity, it results that KDA2 =
4KDA1 and KDB2 = 4KDB1, and eq. (1) can be simplified to:
A
total bound
~ 4KDA1Az 2A
2 z 4KDA1AB = KDAB
 
RT =
4KDA1
2 z 4KDA1Az A
2

z 4KDA1 AB = KDAB z 4KDA1
2B = KDB1
z KDA1
2B2 = KDB1
2

z Anon{specific bound
ð3Þ
When both the radioligand A and the competitor B (DPCPX,
ZM241385, SCH 23390 or YM-09151-2) are the same compound
and the binding is non-cooperative, eq. (3) simplifies to:
A
total bound
~ 4KDA1Az 2A
2 z AB
 
RT =
4KDA1
2 z 4KDA1Az A
2

zABz 4KDA1Bz B
2

zAnon{specific bound
ð4Þ
Goodness of fit was tested according to reduced x2 value given
by the nonlinear regression program. The test of significance for
two different population variances was based upon the F-
distribution (see ref. [25] for details). Using this F test, a probability
greater than 95% (p,0.05) was considered the criterion to select a
more complex equation to fit binding data over the simplest one.
In all cases, a probability of less than 70% (p.0.30) resulted when
one equation to fit binding data was not significantly better than
the other. Results are given as parameter values 6 S.E.M. of
three-four independent experiments.
Results
Striatal pre- versus postsynaptic profile of A2A receptor
antagonists
Dose-response experiments with the six A2AR antagonists
indicated that four compounds (SCH-420814, SCH-58261,
MSX-3 and ZM-241385) had a similar potency (similar minimal
significant effective doses) at inducing locomotor activation (Fig. 1)
and at reducing PCC (Fig. 2). The other two compounds had a
very different profile: KW-6002 produced a strong locomotor
activation already at the dose of 0.3 mg/kg i.p., while it did not
reduce PCC at the highest tested dose (10 mg/kg i.p.). On the
other hand, SCH-442416 produced a very weak locomotor
activation, only significant at doses higher than 3 mg/kg i.p.,
while it significantly decreased PCC already at the dose of 0.1
mg/kg i.p.
In vivo microdialysis with cortical electrical stimulation was used
as an additional in vivo evaluation of the preferential pre- and
postsynaptic activity of SCH-442416 and KW-6002, respectively.
SCH-442416 significantly counteracted striatal glutamate release
induced by cortical stimulation at a dose that strongly reduced
PCC but did not induce locomotor activation (1 mg/kg i.p.; Fig. 3).
On the other hand, KW-6002 did not modify striatal glutamate
release induced by cortical stimulation at a dose that produced a
pronounced locomotor activation but did not reduce PCC (1 mg/
kg i.p.; Fig. 3).
Development of CHO cell-lines expressing A1-A2A or A2A-
D2 receptor heteromers
Cell clones expressing A2AR, A1R-A2AR heteromers or A2AR-
D2R heteromers and control clones expressing A1R or D2R were
generated (see Materials and Methods). First of all, the ability of
A2AR to form heteromers with A1R or D2R in CHO cells was
demonstrated by BRET experiments in cells transiently co-
expressing A2AR-Rluc and A1R-YFP or A2AR-Rluc and D2R-
YFP. A positive BRET signal for energy transfer was obtained
(Fig. 4). The BRET signal increased as a hyperbolic function of the
concentration of the YFP-fusion construct added reaching an
asymptote. As a negative control the BRET pair formed by A2AR-
Rluc and 5-HT2BR-YFP was used. As shown in Figure 4, the
negative control gave a linear non-specific BRET signal. The
significant and hyperbolic BRET signal found for these fusion
proteins indicates that the intermolecular interaction between
A2AR and A1R or A2AR and D2R in CHO cells is specific.
A2AR-D2R and A1R-A2AR heteromerization in stably trans-
fected CHO cells was shown by ligand binding experiments. This
is an indirect approach for the identification of a receptor
heteromer in native tissues or cells [13]. In the A2AR-D2R
heteromer, an allosteric interaction between both receptors in the
heteromer has been described, in which the dopamine D2R
agonist affinity decreases in the presence of an A2AR agonist [14].
In CHO cells stably expressing A2AR and D2R, the affinity of the
D2R for dopamine was determined by competition experiments of
the D2R antagonist [
3H]YM-09151-2 versus dopamine in the
presence (Fig. 5a) or in the absence (Fig. 5b) of the A2AR agonist
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CGS-21680 (200 nM). By fitting data obtained in the absence of
CGS-21680 to eq. 3 (Methods; considering KDA1 = 2.9 nM see
below) the calculated KDB1 was 962 mM. In the presence of CGS-
21680, 5 mM of dopamine was unable to decrease the radioligand
bound and more than 50% of radioligand bound was found in the
presence of 100 mM of dopamine (Fig. 5b). A KDB1 .30 mM was
Figure 2. Blockade by A2AR antagonists of the motor output induced by cortical electrical stimulation. Dose-dependent decrease in the
Power Correlation Coefficient (PCC) induced by the administration of different A2AR antagonists. Results represent means 6 S.E.M. (n = 5–6 per
group). * and **: p,0.05 and p,0.01, respectively in comparison to vehicle-treated animals (0 mg/kg); ANOVA with post-hoc Dunnett’ comparisons,
p,0.5 and p,0.01, respectively).
doi:10.1371/journal.pone.0016088.g002
Figure 1. Locomotor activation in rats induced by A2AR antagonists. Data represent means 6 S.E.M. of the locomotor activity (distance
traveled, in cm, of total accumulated counts) in habituated rats (90 min) during 90 min following the drug administration (n = 6–8 per group). * and
**: p,0.05 and p,0.01, respectively in comparison to vehicle-treated animals (0 mg/kg); ANOVA with post-hoc Newman–Keuls’ comparisons, p,0.5
and p,0.01, respectively).
doi:10.1371/journal.pone.0016088.g001
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estimated and it was shown that CGS-21680 induced a decrease in
the dopamine affinity for D2R. An allosteric interaction in the
A1R-A2AR heteromer has also been described, in which the A1R
agonist affinity decreases in the presence of an A2AR agonist [11].
As shown in Figure 6a, the displacement of the A1R agonist
[3H]R-PIA by CGS21680 was significantly (p,0.001) better fitted
by a biphasic than by a monophasic curve. At low CGS-21680
concentrations, when it binds preferentially to A2AR (at concen-
trations of CGS-21680 ,500 nM, the direct binding of CGS-
21680 to A1R is ,1%, according to the calculated affinity of A1R
for CGS-21680), CGS-21680 decreased the binding of [3H]R-PIA
to the A1R with an IC50 value of 386635 nM (n = 3). At high
CGS-21680 concentrations (.10 mM), the [3H]R-PIA binding
displacement reflects the binding of CGS-21680 directly to the
A1R and the competition between CGS-21680 and R-PIA for the
binding to the A1R. In fact, in the control clone expressing only
A1R, the displacement by CGS-21680 of [
3H]R-PIA only
occurred at CGS-21680 concentrations higher than 10 mM
(Fig. 6b).
A pharmacological characterization of selected cell clones was
performed with competition experiments of radio-labeled antag-
onists of A1, A2A and D2 receptors versus selective agonists or
antagonists. In all cases, the competition curves of the A2AR
antagonist [3H]ZM-241385 (2 nM) versus ZM-241385 (0.1 nM to
11 mM), the D2R antagonist [
3H]YM-09151-2 (0.2 nM) versus
YM-09151-2 (0.01 nM to 11 mM) or the A1R antagonist
[3H]DPCPX (2 nM) versus DPCPX (0.1 nM to 11 mM), were
monophasic, indicating the absence of cooperativity (see Materials
and Methods). By fitting the binding data to eq. 4 (Materials and
Methods), the KD (KD1) values obtained for the antagonists ZM-
241385 or YM-09151-2 were 863 nM and 2.960.3 nM,
respectively, for the chosen A2AR-D2R clone, the KD values
obtained for the A1R and A2AR antagonists were 862 nM
(DPCPX) and 1.860.4 nM (ZM-241385), respectively, for the
chosen A1R-A2AR cell clone and the KD value obtained for A2AR
antagonist (ZM-241385) was 0.960.3 nM for the chosen A2AR
cell clone. Also by fitting the binding data to eq. 4 (Materials and
Methods), the KD value obtained for the A1R antagonist (DPCPX)
was 8.660.9 nM for the A1R cell clone and the KD value obtained
for the D2R antagonist (YM-09151-2) was 0.2360.08 nM for the
D2R cell clone. These values were then used to determine the
affinity constants showed in Tables 1 and 2. The agonists affinity
in each selected clone was determined by competition experiments
using the A2AR antagonist [
3H]ZM-241385 (2 nM) versus the
agonist CGS-21680 (1 nM to 50 mM), the D2R antagonist
[3H]YM-09151-2 (0.2 nM), versus the agonist quinpirole (0.1 nM
to 30 mM), or the A1R antagonist [
3H]DPCPX (2 nM), versus the
agonist R-PIA (1 nM to 50 mM). As it is shown in Tables 1 and 2,
the agonist affinity for A2AR in A2AR, A2AR-D2R or in A2AR-A1R
cells is in the same range as that reported for brain striatum or for
cells expressing human A2AR (between 30 and 250 nM) [7].
Nevertheless, the affinity of the A2AR for the selective agonist
CGS-21680 was slightly but significantly lower when co-expressed
with D2R (see Table 2). A1R (but not A2AR or D2R) agonist
binding showed negative cooperativity (negative DCB values, see
Materials and Methods), both in cells expressing A1R and in cells
co-expressing A1R and A2AR (Tables 1 and 2).
Screening of A2AR antagonists on cells expressing A1-A2A
or A2A-D2 receptor heteromers
To test if selected A2AR antagonists display different selectivity for
A1R-A2AR or A2AR-D2R heteromers, competition experiments
with these ligands were performed using CHO cells expressing
A2AR, A1R-A2AR or A2AR-D2R. We found that none of the six
A2AR antagonists first tested in the in vivo models were able to bind
with moderate affinity to A1R or to D2R in CHO cells expressing
A1R or D2R (data not shown), indicating that these compounds are
specific ligands for A2AR. Competition experiments of [
3H]ZM-
241385 (2 nM) binding versus increasing concentrations of each
A2AR antagonist (1 nM to 100 mM) were performed as indicated in
Methods and binding data from competition experiments were
fitted assuming that receptors are dimers and statistically (F test, see
Materials and Methods) testing whether the competitor (A2AR
antagonists) binding was cooperative (biphasic competition curves;
fitting to eq. 2) or non-cooperative (monophasic competition curves;
Figure 3. Blockade by A2AR antagonists of striatal glutamate release induced by cortical electrical stimulation. (a) Representative
coronal sections of a rat brain, stained with cresyl violet, showing the tracks left by the bipolar stimulation electrode in the orofacial area of the lateral
agranular motor cortex (top) and by the microdialysis probe in the lateral striatum (bottom). (b) Effect of systemic administration of the A2AR
antagonists SCH-442416 and KW-6002 (1 mg/kg, i.p., in both cases) on the increase in glutamate extracellular levels in the lateral striatum induced by
cortical electrical stimulation. Results are expressed as means6 S.E.M. of percentage of the average of the three values before the stimulation (n = 5–
7 per group). Time ‘0’ represents the values of the samples previous to the stimulation. The arrow indicates the time of systemic administration. The
train of vertical lines represents the period of cortical stimulation. *: p,0.05 compared to value of the last sample before the stimulation (repeated-
measures ANOVA followed by Tukey’s test).
doi:10.1371/journal.pone.0016088.g003
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fitting to eq. 3). Since the screened compounds are A2AR
antagonists, competition curves were expected to be monophasic,
assuming that antagonist binding is not cooperative. In fact, in all
cell clones, MSX-2, KW-6002, SCH-420814, ZM-241385 and
SCH-58261 gave monophasic competition curves (fitting binding
data to eq. 2 was not better than fitting to eq. 3; see Methods and
Fig. 7 a–c as an example). Accordingly, the pharmacological
characterization for these compounds gave DCB = 0 and
KDB2 = 4KDB1 (see Table 3). For all compounds, co-transfection
with A1R did not significantly modify their affinity for A2AR. On the
other hand, co-transfection with D2R significantly reduced the
affinity of A2AR for MSX-2, SCH-420814, SCH-58261 and ZM-
241385, from two to about nine times, and did not significantly
modify the affinity of A2AR for KW-6002 (Table 3).
For SCH-442416, a careful statistically-based analysis of the
monophasic or biphasic nature of the competition curves led to an
unexpected finding: in A2AR-D2R cells, competition curves of
[3H]ZM-241385 (2 nM) binding versus increasing concentrations
of SCH-442416 were biphasic (fitting to eq. 2 improves the fitting
to eq. 3; see Methods) (Fig. 7d). Table 4 shows the deduced
pharmacological parameters from competition experiments of
[3H]ZM-241385 versus SCH-442416 in cells expressing A2AR,
A1R-A2AR and A2AR-D2R. In A2AR and A1R-A2AR cells the
curves were monophasic. Accordingly, the pharmacological
characterization gave a DCB values of 0 and a KDB2 = 4KDB1. In
contrast, as mentioned above, in cells expressing A2AR-D2R,
competition curves were biphasic, and binding data were then
fitted to eq. 2 (Methods) and robust parameters were obtained
(Table 4). Thus, in A2AR-D2R cells, SCH-442416 binding showed
a strong negative cooperativity and, consequently, with a marked
loss of affinity (an increase of 600 times in KDB2) respect to cells
expressing A2AR. This is reflected by the B50 value (concentration
competing 50% of radioligand binding), which was more than 40
times higher in A2AR-D2R cells than in A1R-A2AR cells or A2AR
cells.
Figure 4. Identification of receptor heteromers in CHO cells by
BRET saturation curve. BRET experiments were performed with CHO
cells co-expressing A2AR-RLuc and A1R-YFP (A) or A2AR-RLuc and D2R-
YFP (B). Co-transfections were performed with increasing amounts of
plasmid–YFP (0.25 to 4 mg cDNA corresponding to A1R-YFP and 0.5 to
8 mg corresponding to D2R-YFP) whereas the A2AR-RLuc construct was
maintained constant (0.5 mg cDNA). Both fluorescence and luminis-
cence of each sample were measured before every experiment to
confirm similar donor expressions (about 100,000 luminescent units)
while monitoring the increase acceptor expression (10,000–25,000
fluorescent units). As a negative control, linear BRET was obtained in
cells expressing equivalent luminescence and fluorescence amounts
corresponding to A2AR-RLuc, (0.5 mg transfected cDNA) and serotonin
5HT2B-YFP (0.5 to 8 mg transfected cDNA) receptors. The relative
amount of acceptor is given as the ratio between the fluorescence of
the acceptor minus the fluorescence value of cells expressing the donor
alone (YFP) and the luciferase activity of the donor (Rluc). BRET data are
expressed as means 6 S.D. of 4–6 different experiments grouped as a
function of the amount of BRET acceptor.
doi:10.1371/journal.pone.0016088.g004
Figure 5. Allosteric interaction between A2AR and D2R in A2AR-
D2R CHO cells. Competition experiments were performed in
membrane preparations from CHO cells expressing A2AR and D2R with
0.5 nM [3H]YM-09151-2 and increasing concentrations of dopamine
(from 0.1 nM to 30 mM) in the absence (a) or in the presence (b) of
200 nM CGS-21680 as indicated in Methods. Data represent means 6
S.E.M. of a representative experiment performed with triplicates.
doi:10.1371/journal.pone.0016088.g005
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Discussion
An important finding of the present study is that several A2AR
antagonists previously thought as being pharmacologically similar
present different striatal pre- and postsynaptic profiles. Six
compounds already known as selective A2AR antagonists were
first screened for their ability to block striatal pre- and postsynaptic
A2ARs with in vivo models. Locomotor activation was used to
evaluate postsynaptic activity while PCC reduction was used to
determine presynaptic activity (see Introduction). Two com-
pounds, SCH-442416 and KW-6002, showed preferential pre-
and postsynaptic profiles, respectively, and four compounds,
MSX-3, SCH-420814, SCH-58261 and ZM-241385, showed
mixed pre-postsynaptic profiles. Combining in vivo microdialysis
with cortical electrical stimulation was used as an additional in vivo
evaluation of presynaptic activity of SCH-442416 and KW-6002.
In agreement with its preferential presynaptic profile, SCH-
442416 significantly counteracted striatal glutamate release
induced by cortical stimulation at a dose (1 mg/kg i.p.) that
strongly reduced PCC but did not induce locomotor activation.
On the other hand, according to its preferential postsynaptic
profile, KW-6002 did not modify striatal glutamate release
induced by cortical stimulation at a dose (1 mg/kg i.p.) that
produced a pronounced locomotor activation but did not
counteract PCC. In a previous study, we reported that intrastriatal
perfusion of MSX-3 almost completely counteracted striatal
glutamate release induced by cortical electrical stimulation [5],
which agrees with its very effective reduction of PCC shown in the
present study.
Another important finding of the present study is that at least
part of these pharmacological differences between A2AR antago-
nists can be explained by the ability of pre- and postsynaptic A2AR
to form different receptor heteromers, with A1R and D2R,
respectively [4–6,11,14]. Radioligand-binding experiments were
performed in CHO cells stably expressing A2AR, A2AR-D2R
heteromers or A1R-A2AR heteromers to determine possible
differences in the affinity of these compounds for different A2AR
heteromers. Co-expression with A1R did not significantly modify
the affinity of A2AR for the different ligands, but co-expression
with D2R decreased the affinity of all compounds, with the
exception of KW-6002. The structural changes in the A2AR
induced by heteromerization with the D2R could be detected not
only by antagonists but also by agonists. Indeed, the affinity of the
selective A2AR agonist CGS-21680 was reduced in cells co-
Figure 6. Allosteric interaction between A1R and A2AR in A1R-
A2AR CHO cells. Competition experiments were performed in
membrane preparations from CHO cells expressing A1R or A1R and
A2AR with 12 nM [
3H]R-PIA versus increasing concentrations of the A2AR
agonist CGS-21680 as indicated in Methods. Data represent means 6
S.E.M. of a representative experiment performed with triplicates.
doi:10.1371/journal.pone.0016088.g006
Table 1. Pharmacological parameters for agonist binding to
A1R, A2AR and D2R in A1R, A2AR and D2R CHO cells.
Parameters A2AR cells A1R cells D2R cells
KDB1 90630 nM 1363 nM 120660 nM
KDB2 3606120 nM 160.3 mM 4806240 nM
DCB 0 21.3 0
B50 180660 nM 110630 nM 2406120 nM
Binding data from competition experiments were fitted assuming that
receptors form homodimers, and cooperativity (DCB ? 0, fitting to eq. 2;
Materials and Methods) or non-cooperativity (DCB = 0, fitting to eq. 3; Materials
and Methods) in competitor ligand binding was statistically tested (F test). KDB1
and KDB2 are, respectively, the equilibrium dissociation constants of the first and
second binding of B (the A1R, A2AR, or D2R agonists: R-PIA, CGS-21680 or
quinpirole, respectively) to the dimer. DCB is the ‘‘dimer cooperativity’’ index for
the binding of the ligand B, and B50 is the concentration providing half
saturation for B. Data are mean 6 S.E.M. values of three experiments.
doi:10.1371/journal.pone.0016088.t001
Table 2. Pharmacological parameters for agonist binding to
A1R-A2AR and A2AR-D2R CHO cells.
Parameters A2AR-D2R cells A2AR-A1R cells
A2AR D2R A2AR A1R
KDB1 200640 nM* 1.260.6 mM 70610 nM 0.760.3 nM
KDB2 0.860.4 mM 4.862.4 mM 280640 nM 1.160.5 mM
DCB 0 0 0 22.6
B50 0.460.08 mM 2.461.2 mM 140620 nM 30610 nM
Binding data from competition experiments were fitted assuming that
receptors (also when heteromerizing) form homodimers, and cooperativity
(DCB ? 0, fitting to eq. 2; Materials and Methods) or non-cooperativity (DCB = 0,
fitting to eq. 3; Materials and Methods) in competitor ligand binding was
statistically tested (F test). KDB1 and KDB2 are, respectively, the equilibrium
dissociation constants of the first and second binding of B (the A1R, A2AR, or
D2R agonists: R-PIA, CGS-21680 or quinpirole, respectively) to the dimer. DCB is
the ‘‘dimer cooperativity’’ index for the binding of the ligand B, and B50 is the
concentration providing half saturation for B. Data are mean 6 S.E.M. values of
three experiments.
*: p,0.05 compared to KDB1 values in A1R-A2AR and A2AR cells (Table 1); one-
way ANOVA, followed by Newman-Keuls test.
doi:10.1371/journal.pone.0016088.t002
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Figure 7. Binding of the A2AR antagonists KW-6002 and SCH-442416 to A1R-A2AR and A2AR-D2R CHO cells. Competition experiments of
[3H]ZM-241385 (2 nM) versus increasing concentrations of KW-6002 (a and c) or SCH-442416 (b and d) were performed as indicated in Methods in
membrane preparations from CHO cells expressing A1R and A2AR (a and b) or A2AR and D2R (c and d). Data are means 6 S.E.M. of a representative
experiment performed with triplicates.
doi:10.1371/journal.pone.0016088.g007
Table 3. Pharmacological parameters for A2AR antagonist
binding to A2AR, A1R-A2AR and A2AR-D2R CHO cells.
KD1 (nM) A2AR cells A1R-A2AR cells A2AR-D2R cells
ZM241385 0.960.3 1.860.4 863*
SCH58261 3.360.3 4.760.6 2368*
MSX2 3.260.2 4.260.3 762*
KW6002 100610 100620 160670
SCH420814 0.560.1 1.160.1 2.760.8*
Competition experiments of [3H]ZM-241385 (2 nM) binding versus increasing
concentrations of A2A receptor antagonists were performed as indicated in
Methods in membrane preparations from CHO cells expressing A2AR or A1R and
A2AR or A2AR and D2R. Binding data were fitted assuming that receptors (also
when heteromerizing) form homodimers, and cooperativity (DCB ? 0, fitting to
eq. 2; Materials and Methods) or non-cooperativity (DCB = 0, fitting to eq. 3;
Materials and Methods) for competitor ligand binding was statistically tested (F
test). Only KDB1 values (equilibrium dissociation constant of the first binding of
B: ZM-241385, MSX-2, SCH-58261, SCH-420814 or KW-6002) are shown, since
the analysis demonstrated non-cooperativity for the five A2AR antagonists. Data
are mean 6 S.E.M. values of three experiments.
*: p,0.05 compared to KDB1 values in A2AR cells; one-way ANOVA, followed by
Newman-Keuls test.
doi:10.1371/journal.pone.0016088.t003
Table 4. Pharmacological parameters for SCH-442416
binding to A2AR, A1R-A2AR and A2AR-D2R CHO cells.
Parameters A2AR cells A1R-A2AR cells A2AR-D2R cells
KDB1 2.060.3 nM 2.460.4 nM 764 nM
KDB2 862 nM 1062 nM 562 mM**
DCB 0 0 22.3
B50 4.060.6 nM 4.860.8 nM 190680 nM**
Competition experiments of [3H]ZM-241385 (2 nM) binding versus increasing
concentrations of SCH-442416 were performed as indicated in Methods in
membrane preparations from CHO cells expressing A2AR or A1R and A2AR or
A2AR and D2R. Results were fitted assuming that receptors (also when
heteromerizing) form homodimers, and cooperativity (DCB ? 0, fitting to eq. 2;
Materials and Methods) or non-cooperativity (DCB = 0, fitting to eq. 3; Materials
and Methods) of SCH-442416 binding was statistically tested (F test). KDB1 and
KDB2 are, respectively, the equilibrium dissociation constants of the first and
second binding of B (SCH-442416) to the dimer. DCB is the ‘‘dimer cooperativity’’
index for the binding of the ligand B, and B50 is the concentration providing half
saturation for B. Data are mean 6 S.E.M. values of three experiments.
**: p,0.01, respectively compared to the KDB2 and B50 values in A2R and A1R-
A2AR cells; Kruskal-Wallis, followed by Dunn’s test.
doi:10.1371/journal.pone.0016088.t004
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transfected with the D2R. When trying to explain the differential
action of SCH-442416 observed in vivo, it is interesting to note that
SCH-442416 showed a much higher affinity for the A2AR in a
presynaptic-like than in a postsynaptic-like context. The binding of
SCH-442416 to the A2AR-D2R heteromer displayed a strong
negative cooperativity, phenomenon that was not observed for the
binding of SCH-442416 to the A1R-A2AR heteromer. This
negative cooperativity explains the pronounced decrease in affinity
of A2AR in cells expressing A2AR-D2R heteromers (B50 values 40
times higher in cells expressing A2AR-D2R than A1R-A2AR
heteromers).
The loss of affinity of A2AR upon co-expression of D2R was
much less pronounced for ZM-241385, SCH-58261, MSX2 or
SCH-420814, for which the affinity was reduced from two to
about nine fold. Taking into account that these A2AR antagonists
behave similarly than the A2AR agonist CGS-21680 in terms of
binding to A1R-A2AR and A2AR-D2R heteromers, it is expected
that these four compounds compete equally for the binding of the
endogenous agonist at pre- and at postsynaptic sites. This would fit
with the in vivo data, which shows that these compounds have a
non-preferred pre-postsynaptic profile. Yet, KW-6002 was the
only antagonist whose affinity was not significantly different in cells
expressing A2AR, A1R-A2AR heteromers or A2AR-D2R hetero-
mers. Thus, KW-6002 showed the best relative affinity for A2AR-
D2R heteromers of all coumpounds, which can at least partially
explain its preferential postsynaptic profile.
The present results support the notion that receptor heteromers
may be used as selective targets for drug development. Main
reasons are the very specific neuronal localization of receptor
heteromers (even more specific than for receptor subtypes), and a
differential ligand affinity of a receptor depending on its partner
(or partners) in the receptor heteromer. In the striatum, A2AR
provides a particularly interesting target, eventually useful for a
variety of neuropsychiatric disorders. A2AR-D2R and A1R-A2AR
heteromers are segregated in different striatal neuronal elements.
While A2AR-D2R heteromers are located postsynaptically in the
dendritic spines of the indirect MSNs [4–6,14], A1R-A2AR
receptor heteromers are located presynaptically in glutamatergic
terminals contacting the MSNs of the direct pathway [5,11,14].
Blocking postsynaptic A2AR in the indirect MSN should potentiate
D2R-mediated motor activation, which is a strategy already used
in the development of anti-parkinsonian drugs [26–28]. However,
blocking A2AR in glutamatergic terminals to the direct MSN could
potentially be useful in dyskinetic disorders such as Huntington’s
disease and maybe in obsessive-compulsive disorders and drug
addiction [5]. The present results give a mechanistic explanation
to the already reported antiparkinsonian activity of KW-6002
[27,28] and suggest that SCH-442416 could be useful in dyskinetic
disorders, obsessive-compulsive disorders and in drug addiction.
Medicinal chemistry and computerized modeling should help
understanding the molecular properties that determine the
particular pharmacological profile of SCH-442416 and KW-
6002, which may be used as lead compounds to obtain more
effective antidyskinetic and antiparkinsonian compounds, respec-
tively. It will also be of importance to take into account potential
changes in the expression of pre- and postsynaptic A2ARs and in
their respective heteromers which can occur in those mentioned
neuropsychiatric disorders. For instance, dopamine denervation
seems to differentially modify the expression of striatal A2AR, A1R
and D2R [28–31]. This could be addressed by applying the in vivo
methodology here described to animal models.
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